Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Operating Expenses (2017 - 2025)

Agios Pharmaceuticals' Other Operating Expenses history spans 8 years, with the latest figure at $1.7 million for Q2 2025.

  • For Q2 2025, Other Operating Expenses rose 13.85% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $2.8 million, down 98.62%, while the annual FY2024 figure was $200.0 million, N/A changed from the prior year.
  • Other Operating Expenses reached $1.7 million in Q2 2025 per AGIO's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $200.0 million in Q3 2024 to a low of -$9.9 million in Q4 2022.
  • Average Other Operating Expenses over 5 years is $15.2 million, with a median of $1.9 million recorded in 2021.
  • The largest YoY upside for Other Operating Expenses was 122.15% in 2022 against a maximum downside of 473.29% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at $2.6 million in 2021, then plummeted by 473.29% to -$9.9 million in 2022, then skyrocketed by 111.25% to $1.1 million in 2023, then skyrocketed by 17950.54% to $200.0 million in 2024, then crashed by 99.15% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Other Operating Expenses are $1.7 million (Q2 2025), $1.1 million (Q1 2025), and $200.0 million (Q3 2024).